<DOC>
	<DOCNO>NCT01680952</DOCNO>
	<brief_summary>This study compare efficacy safety Extended Release Tacrolimus ( Advagraf® ) + Sirolimus ( Rapamune® ) , versus Extended Release Tacrolimus ( Advagraf® ) + Mycophenolate mofetil Kidney Transplant Patients .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Extended Release Tacrolimus ( Advagraf® ) + Sirolimus ( Rapamune® ) , Versus Extended Release Tacrolimus ( Advagraf® ) + Mycophenolate Mofetil Kidney Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Male female patient age 20 year Patient judge would benefit Extended Release Tacrolimus ( Advagraf® ) treatment investigator Patients give write informed consent Patient recipient primary recipient primary ( live kidney transplant , cadaveric donor . ) Patients receive ABO compatible donor kidney . Complementdependent Cytotoxic Crossmatch : CDC ) result : negative Female patient child bear potential must negative urine serum pregnancy test within 7 day prior enrollment upon hospitalization Patient previously receive organ transplant kidney . Patient known hypersensitivity tacrolimus , Sirolimus ( Rapamune® ) , Mycophenolate mofetil . Desensitization HLAidentical Heart Disease ; Heart failure ( symptom , EF &lt; 45 % ) Lung Disease ; Significant chronic obstructive pulmonary disease , restrictive lung disease Patient uncontrolled concomitant infection ( include Hepatitis B , Hepatitis C ) unstable malignant tumor history 5years prior enrollment . ( except , squamous cell carcinoma ) Patient receive kidney transplant nonheart beat donor Cold ischemic time &gt; 30hrs Elevated AST and/or ALT level great 3 time upper value normal range investigational site ( ANC ) &lt; 1,500/mm3 , ( WBC ) &lt; 2,500/ mm3 , ( PLT ) &lt; 100,000/ mm3 ATG : Antithymocyte globulin induction Medical condition could interfere study objective . Patient currently take take investigational product 30 day prior enrollment . Patient currently take take prohibited medication 28 day prior enrollment . Patient judge adequate investigator owe reason Patient pregnant lactating . Recipient donor know seropositive human immunodeficiency virus . ( HIV )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>RECORD study</keyword>
</DOC>